Specific Diagnostics announces the first order forms in Europe
MOUNTAIN VIEW, CALIFORNIA., October 4, 2021 / PRNewswire-PRWeb / – Specific Diagnostics today announced that it has signed multi-year reagent rental agreements with two clinical microbiology laboratories in France, marking the commercialization of the transformative rapid AST instrument Reveal from Specific. These purchases follow 11 successful studies across France and England comprising over 1,400 positive blood culture samples, giving an overall accuracy of ≈ 97.6% and an average time to results of approximately 5 hours.
Reveal’s low cost, high throughput, large menu, and small footprint are all suited for large-scale adoption. The modular system design ensures no single point of failure, 100% uptime and gradual adoption by hospitals of all sizes. The unique Reveal Dashboard ™ provides the lab with easy-to-use real-time tools to monitor instrument usage, infection and resistance trends.
“Our direct teams in the field in both France and England have seen great momentum for evaluation and now adoption for clinical use, ”said Dr. Paul Rhodes, CEO of Specifique. “We find almost universal interest in rapid AST for blood infection, and much in high emergency isolates as well, in all the distinguished laboratories we visit in Europe. The need is widely recognized. Now that we have demonstrated the accuracy, robustness, ease of use and with the comparatively low price and high throughput that we offer, these appear to be the first of many conversions in clinical use. Our entire team has worked for years to get there and are very happy that the Reveal System is now available to help hospital teams better treat patients with the deadliest and fastest infections. “
Specific’s direct team expands to Spain and other countries in Europe and the Middle East in the coming months, and will be joined by the continent-wide sales organization of Specific’s channel partner to continue bringing Reveals to hospitals around the world. Europe.
Specific Diagnostics has developed in vitro diagnostic systems based on a unique and patented metabolomic signature technology that allows rapid detection and identification of microorganisms as they grow in culture. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as to dilutions of isolates. Specific is based in Mountain View, California, with subsidiaries in Ireland, France and the United Kingdom.
For press inquiries, please contact: [email protected]
Jeffrey Holman, Specific diagnostics, 3176179153, [email protected]